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Abstract
Background: Musculoskeletal problems such as low back pain, neck, knee and shoulder pain are leading causes of disability and
activity limitation in adults and are most frequently managed within primary care. There is a clear trend towards large, high
quality trials testing the effectiveness of common non-pharmacological interventions for these conditions showing, at best, small
to moderate benefits. This paper summarises the main lessons learnt from recent trials of the effectiveness of non-
pharmacological therapies for common musculoskeletal conditions in primary care and provides agreed research priorities for
future clinical trials.
Methods: Consensus development using nominal group techniques through national (UK) and international workshops. During
a national Clinical Trials Thinktank workshop in April 2007 in the UK, a group of 30 senior researchers experienced in clinical
trials for musculoskeletal conditions and 2 patient representatives debated the possible explanations for the findings of recent
high quality trials of non-pharmacological interventions. Using the qualitative method of nominal group technique, these experts
developed and ranked a set of priorities for future research, guided by the evidence from recent trials of treatments for common
musculoskeletal problems. The recommendations from the national workshop were presented and further ranked at an
international symposium (hosted in Canada) in June 2007.
Results: 22 recommended research priorities were developed, of which 12 reached consensus as priorities for future research
from the UK workshop. The 12 recommendations were reduced to 7 agreed priorities at the international symposium. These
were: to increase the focus on implementation (research into practice); to develop national musculoskeletal research networks
in which large trials can be sited and smaller trials supported; to use more innovative trial designs such as those based on stepped
care and subgrouping for targeted treatment models; to routinely incorporate health economic analysis into future trials; to
include more patient-centred outcome measures; to develop a core set of outcomes for new trials of interventions for
musculoskeletal problems; and to focus on studies that advance methodological approaches for clinical trials in this field.
Conclusion: A set of research priorities for future trials of non-pharmacological therapies for common musculoskeletal
conditions has been developed and agreed through national (UK) and international consensus processes. These priorities
provide useful direction for researchers and research funders alike and impetus for improvement in the quality and methodology
of clinical trials in this field.
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Musculoskeletal problems such as low back pain, neck,
knee and shoulder pain are leading causes of disability
and activity limitation in adults and are most frequently
managed within primary care in the UK [1,2]. For exam-
ple, non-specific low back pain has a one-month preva-
lence of 35–37% [3] and lifetime prevalence of between
49–70% [4], leading to large health care costs and loss of
productivity [5]. Around one third of episodes of back
pain result in persistent disabling symptoms [6] and this
is similar across other musculoskeletal problems such as
neck or shoulder pain [7] and knee pain [1,8]. In older
people, the most frequent cause of pain and disability is
joint pain. Recent estimates suggest up to 8.5 million peo-
ple in the UK are affected by joint pain [9]. The primary
prevention of these conditions has proven difficult, there-
fore management approaches focus on prevention of
unnecessary limitations in activity and maximising partic-
ipation.
Non-pharmacological therapies have a central role in the
management of these common musculoskeletal condi-
tions in primary care. Treatment options include advice
and education, reassurance, help with self-management
in terms of symptom control, coping strategies and pre-
vention of further chronicity, in addition to individual
exercise programmes and manual therapy. Clinical trials
to date have shown some positive results for these inter-
ventions, but it is clear that they do not suit all patients
[10]. The evaluation of these types of interventions has
grown substantially over the last decade, evidenced by the
increasing number of published randomised clinical trials
[11] coupled with initiatives to try to improve their meth-
odological quality [12]. Key features of high quality ran-
domised clinical trials (RCTs) include recruitment of a
sample representative of the patient group, randomisa-
tion of individuals, an appropriate control or comparison
treatment (sometimes a placebo), concealment of the
intervention from both patients and therapists, and an
intention-to-treat analysis.
However, designing RCTs of non-pharmacological inter-
ventions that accurately reflect the complexities of clinical
care is challenging. Complex interventions try to change
the behaviour of patients or practitioners, for example,
through adhering to healthcare advice or a home exercise
programme [13]. Thus they depend on a range of factors,
including the beliefs and behaviours of the health profes-
sional and the beliefs and adherence of the patient. Typi-
cally, non-pharmacological therapies are delivered as part
of a package of care rather than as a single treatment alone
[14], further complicating the design of trials to test treat-
ment effectiveness. The methodological challenges posed
by studying 'complex' interventions [13] include the need
to define the various components of the intervention
including their anticipated specific and non-specific
effects, determine the characteristics of patients that may
respond to a multi-modal intervention and ensure con-
sistent and high quality delivery of the treatment pro-
gramme.
In line with systematic reviews in this area [15-20], there
is a clear trend towards large, high quality RCTs showing,
at best, small to moderate benefits from non-pharmaco-
logical interventions for patients with musculoskeletal
pain [e.g. [21,22]] and either no differences or very small
differences between the effectiveness of different
approaches [23,24]. Examples of pragmatic trials recently
published include those from our research groups [22,25-
28] and others [21,29-33]. In the field of low back pain
alone, there have been several recent, high-quality trials
showing only small differences in improvements of disa-
bility, of questionable clinical significance, between vari-
ous types of non-pharmacological therapies, or between
these and usual primary care [21,25,29,32,34,35].
These 'negative' findings are strongly at odds with the
experiences of health care practitioners who see individ-
ual patients improve, often dramatically, leading practi-
tioners to believe in the effectiveness of specific
interventions. These issues were the focus of an initiative
to develop agreed priorities to guide the future research
agenda for intervention studies in this field. The process
involved a national Clinical Trials Thinktank workshop
held in the UK and, subsequently, an international sym-
posium held in Canada during the World Confederation
of Physical Therapy congress in 2007. The aim was to pro-
vide an arena for discussion and to develop agreed recom-
mendations for future studies testing the effectiveness of
non-pharmacological interventions for common muscu-
loskeletal pain. This paper provides an overview of the key
explanations from the expert participants for the results of
recent high quality clinical trials of non-pharmacological
interventions, summarises the recommendations made
by experts in this field and presents the agreed set of pri-
orities for the future research agenda for the evaluation of
non-pharmacological interventions for common muscu-
loskeletal problems.
Methods
A set of agreed priorities for future research investigating
the effectiveness of interventions for common muscu-
loskeletal problems was developed through a process of
consensus, in two stages reflecting national (UK) and
international perspectives.
Stage 1 comprised the Clinical Trials Thinktank in the UK
with national experts in clinical trials for common musc-
uloskeletal conditions, held at the Arthritis Research Cam-
paign National Primary Care Centre at Keele University.Page 2 of 10
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from the fields of musculoskeletal pain and two patient
representatives addressed a series of questions through
discussion and debate. The professionals came from the
following backgrounds: physiotherapy and related allied
health disciplines including occupational therapy and
podiatry, primary care including general practice, public
health medicine, health services research, chiropractic,
rheumatology, clinical trials methodology, biostatistics
and health economics. Several participants were also
involved in leading or contributing to the funding agen-
das of national research funding agencies. The questions
were:
1. What have we learned from conducting high quality
RCTs of non-pharmacological interventions for muscu-
loskeletal pain presenting to primary care?
2. What recommendations can be made for future studies
of non-pharmacological interventions?
3. Which of these recommendations are agreed priorities?
Invited delegates were either experienced researchers who
had published clinical trials or protocols of clinical trials
of non-pharmacological interventions for common mus-
culoskeletal problems or patients representatives with
musculoskeletal problems. During the workshop, partici-
pants presented brief summaries of example trials [21-
26,36-39], and participated in themed discussions specif-
ically addressing each of the above questions. In each ses-
sion, the questions were considered in light of the patient
population, the interventions delivered and the outcomes
measured. Following these discussions, participants
developed a set of recommendations for the design and
conduct of studies investigating the effectiveness of non-
pharmacological interventions for musculoskeletal condi-
tions using a nominal group technique (NGT). This is a
group-based method through which information is gath-
ered from experts in a structured way and consensus on a
particular topic is facilitated [40]. Led by facilitators,
workshop participants generated initial opinions and rec-
ommendations for future clinical trials, participants then
contributed their suggestions to the group for discussion,
these suggestions were clarified and tabulated and then
participants independently ranked each recommendation
according to their view of their relative importance. On a
5-point Likert scale ranging from 'Strongly Disagree' to
'Strongly Agree', participants ranked their agreement with
each of the recommendations. These rankings were tabu-
lated and presented back to the group for further discus-
sion. For the purposes of prioritising those for which a
high level of agreement was evident, the consensus level
was set as those recommendations that received a median
ranking of 4 or more and on which more than 75% of par-
ticipants agreed or strongly agreed. NGT has been
described as a 'hybrid' of the Delphi method and the focus
group [41]. It was particularly suitable for this initiative
since all participants in the group are given the opportu-
nity to contribute ideas and all rankings are completed
privately and independently, thus limiting the potential
for participants to influence each other's recommenda-
tions. The output from the UK-based Thinktank work-
shop was therefore considered to be a list of nationally
agreed recommendations to guide the future research
agenda in this field.
In Stage 2, the recommendations from the UK Thinktank
were taken to the largest international physical therapy
congress in order to be further prioritised by colleagues
from other countries. The recommendations were pre-
sented to an international forum, through a specific sym-
posium, at the World Confederation of Physical Therapy
in Vancouver, Canada in June 2007 http://www.wcpt.org
where 133 participants considered the recommendations
and prioritised them, again using a process of independ-
ent ranking using the same Likert scale described previ-
ously. The Confederation is a non-profit organisation
comprising 92 member organisations which, together,
represent more than 250,000 physical therapists world-
wide. Twenty-four countries were represented among the
133 participants, mostly from North America and West-
ern Europe, but also including South America, Asia and
South Africa. More than half identified themselves as
researchers (n = 80, 62.5%) with the others comprising
practitioners, educators, managers and others. Following
the ranking process at the international symposium, using
the same criterion for consensus, the output was an inter-
nationally agreed set of priority recommendations.
Results
In Stage 1, 32 national (UK) experts participated in the UK
Thinktank workshop over two days. The following pro-
vides a summary of key findings for each of the three ques-
tions addressed within the workshop.
1. What have we learned from conducting high quality 
RCTs of non-pharmacological interventions for 
musculoskeletal pain in primary care?
From the selection of example trials presented, several
observations were made and discussed at length within
the workshop. Firstly, when common non-pharmacologi-
cal interventions were compared with other primary care
interventions, such as care from general practitioners
(GP), then trials generally showed significant differences
between groups. For example, a pragmatic RCT by Hay
and colleagues [22] compared usual primary care with
community physiotherapy for older adults with chronic
knee pain, and showed short-term benefits of physiother-
apy over usual GP care. Secondly, when two or more dif-Page 3 of 10
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were compared, then trials appeared most likely to show
no significant differences between groups. For example,
no difference between two or more physiotherapy
approaches for low back pain patients [23,25,29] or neck
pain patients [26]. Thirdly, when the primary outcome
data were plotted on a graph over time, the similarity of
findings, in terms of changes in pain and function, across
trials of low back pain, neck pain, knee pain and shoulder
pain was striking, irrespective of the specific interventions
being tested.
Several explanations for the trends in the findings of
recent trials were discussed. Given the similarity in trial
findings, one key explanation was that non-pharmacolog-
ical interventions in primary care provide little benefit for
patients with musculoskeletal conditions and do not
change the natural course of these conditions over time.
Patient selection was discussed in relation to the problem
of heterogeneity of the samples within previous trials,
such that the average treatment effect masks a wide range
of individual responses to treatment, including for exam-
ple patients who benefit a great deal along with those who
benefit little or not at all. Participants suggested there has
been inadequate identification of important patient sub-
groups in previous trials. Discussion highlighted that pre-
vious trials had been based on a traditional, but perhaps
unrealistic, expectation of moderate to large effects of
non-pharmacological, primary care-based interventions
for patients with common musculoskeletal patients. In
fact, the overall message from previous trials is one of
small and often short-term effects, some of which may be
clinically meaningful whilst others may not. If the results
of multiple high quality clinical trials give the 'true' pic-
ture for the majority of patients, then dramatic improve-
ments seen in individual patients are not representative of
the impact of non-pharmacological therapies in general
for populations with musculoskeletal conditions. Power-
ing clinical trials to compare different interventions to
show anything other than small differences between
groups appeared particularly unrealistic.
Participants debated the likelihood that previous clinical
trials' investigators had overestimated the specific treat-
ment effects of interventions and underestimated the
non-specific treatment effects, such as the attention, sup-
port and empathy provided by a health care practitioner
and individual patients' and practitioners' preferences and
expectations. This was felt to help explain the lack of sig-
nificant differences between interventions seen in previ-
ous trials. A further explanation was, that despite many
trials now incorporating recommended and validated
outcome measures, these may still be failing to capture
what is really important to patients. There was a general
view that there continues to be inadequate measurement
of outcomes that are important to patients, in terms of
both the timing of outcome assessments and the con-
structs being captured by available validated outcome
measures, such as pain-related disability. A final explana-
tion debated to what degree the interventions within pre-
vious trials were effectively applied, with some
participants of the view that there has been insufficient
attention to the assessment of skills and competencies of
clinicians providing the interventions and their adherence
to the intervention protocols stipulated by the trial proce-
dures. Following these discussions, participants generated
their recommendations for future studies.
2. What recommendations can be made for future studies 
of non-pharmacological interventions?
As a result of the independent suggestions from partici-
pants, a list of 22 recommendations was generated, pre-
sented in Table 1. Following clarification and discussion,
these were then subjected to independent ranking.
3. Which of these recommendations are agreed priorities?
From the original set of 22 recommendations, an agreed
list of 12 priorities was generated as a result of the inde-
pendent ranking, highlighted in Table 1. The 12 recom-
mendations were ranked, again independently, at the
WCPT international symposium with 133 participants
from 24 different countries. Of the 12 recommendations,
7 reached our agreed level of consensus and are high-
lighted in Table 1. Those describing themselves as
researchers and those describing themselves as practition-
ers selected the same top 7 recommendations in their
ranking exercise. There was clear agreement on the need
for future research to focus further on implementation
(research into practice) for musculoskeletal conditions,
the potential benefit of developing national musculoskel-
etal research networks through which support for trials
could be provided, to develop more innovative trial
designs such as those based on stepped care and sub-
grouping for targeted treatment approaches and for health
economic analysis to become a common component of
future clinical trials. In addition, the recommendations to
include more patient-centred outcomes in trials, to
develop a core set of outcomes for new trials to allow
comparisons in the future and to conduct studies that
advance methodological approaches for clinical trials also
met our consensus criteria. The implications of these pri-
ority recommendations are discussed below.
Discussion
Through two focused workshops, this initiative has devel-
oped a set of priorities that can guide future research test-
ing the effectiveness of non-pharmacological, primary
care-based interventions for common musculoskeletal
conditions. The recommendations aim to encourage high
quality and innovative clinical trials that can answer thePage 4 of 10
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and their musculoskeletal pain patients. It is important to
stress that the key feature of our approach in this study is
the consensus of experts, including patients, in the field of
trials of non-pharmacological primary care-based inter-
ventions for musculoskeletal conditions. It was not our
intention to present the priorities as the sole priorities for
research in this field, but to bring experts together to gen-
erate and agree a set of priorities for interventions studies
that could be published and used to influence future
research and funding strategies.
Agreed priority – Focus on implementation
The desire to implement research findings into practice
has increased in priority with the amount of evidence now
generated in the musculoskeletal pain literature. Simulta-
neously there has been an acknowledgement that the evi-
dence alone cannot be implemented without facilitation
Table 1: Summary of recommendations for future trials of non-pharmacological interventions for musculoskeletal problems
Recommendation Reached consensus in 
UK Clinical Trials 
Thinktank
Reached consensus in 
International 
Symposium
Level of 
agreement (% 
agreement)*
1 Focus on implementation (research into practice) for 
musculoskeletal conditions
* * 90.1%
2 Develop national musculoskeletal research networks in 
which large trials can be sited and smaller trials supported
* * 87.9%
3 Develop more innovative trial designs (such as those 
based on stepped care, subgrouping patients and targeting 
treatment)
* * 83.2%
4 Include more patient-individualised outcomes * * 83.9%
5 Develop core sets of outcomes for new trials to allow 
comparisons across trials
* * 81.2%
6 Include cost-effectiveness analysis within clinical trials * * 77.3%
7 Focus on studies that advance clinical trials methodology * * 77.1%
8 Compare non-pharmacological interventions to 'real life' 
controls 
(groups receiving no treatment or usual primary care)
* 77.4%
9 Investigate the specific versus non-specific effects of 
treatments to determine what it is about the 
interventions that is effective
* 73.8%
10 Develop intervention models that match the natural 
history of common musculoskeletal problems (long-term 
conditions require long-term model of care such as that 
used in diabetes or asthma)
* 69.9%
11 Conduct pilot studies to develop innovative trial designs * 68.2%
12 Capture the effects of treatment earlier 
(eg. weeks not months)
* 65.4%
13 Distinguish first the natural history of conditions and then 
look at effects of interventions
-
14 Test treatments that are already in practice within future 
trials
-
15 Focus more on phase 1 and 2 studies (modelling and 
piloting) before proceeding to clinical trials
-
16 Focus on earlier timing of interventions in the history of 
the musculoskeletal problem
-
17 Use new trial designs but use them to answer specific 
research questions more efficiently
-
18 Go back to some of the key basics within trials and 
improve the measurement of process issues, improve 
outcomes and ensure quality of treatment
-
19 Explore how to engage private providers of care in 
research and clinical trials in more optimal ways
-
20 Use equivalence and non-inferiority trials rather than the 
traditional superiority trial design, when appropriate
-
21 Develop 'mega-trials' 
(national and multi-national clinical trials)
-
22 Make better use of data from previous trials -
* Percentage agreement (agreed or strongly agreed) by 133 participants of International SymposiumPage 5 of 10
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still uncertain. Development of clinical guidelines has
been one mechanism for enhancing uptake of research
into practice [46]. For example, exercise is recommended
as a core treatment by the National Institute of Health and
Clinical Excellence in the UK in their recent osteoarthritis
guidelines [47] as a result of evidence from high quality
RCTs of non-pharmacological interventions [e.g.
[22,28,36,48]]. Unfortunately implementation strategies
for clinical guidelines are complex and studies in this field
are challenging. It is not surprising therefore that this rec-
ommendation was highly rated by both national and
international participants in this consensus study.
Agreed priority – Develop national Musculoskeletal 
Research Networks
This priority is timely, and reflects a growing commitment
of the research community to adopt a collaborative, rather
than competitive, approach to clinical research. It is
increasingly unrealistic for lone researchers, working in
isolation, to produce high quality RCTs and other clinical
studies required to answer important research questions.
As an example of the increasing recognition of this, in
October 2007 the Arthritis Research Campaign (arc), the
fourth largest medical charity in the UK and the only one
solely dedicated to research in musculoskeletal condi-
tions, launched a new initiative. They formed seven Clin-
ical Studies Groups, to support clinical trials and related
research within the UK [49]. In partnership with the UK
Comprehensive Research Network, the Clinical Studies
Groups will develop nationally agreed strategic plans for
clinical research in arthritis and related musculoskeletal
conditions. This initiative aims to be inclusive, with the
expressed aim of encouraging and facilitating clinician
engagement in research in a variety of ways; for example
by helping develop research questions, by developing and
delivering novel interventions, through to being Principal
Investigators on named projects. Full details of the arc
Clinical Studies Groups can be found on http://
www.arc.org.uk but this provides one key example of how
this recommendation can be taken forward at a national
level.
Agreed priorities – Develop more innovative trial designs 
and studies that advance methodological approaches
Ideally, strictly designed RCTs are carried out among
homogeneous groups of patients, in order to limit indi-
vidual variation and optimize prognostic similarity of
intervention groups. The drawback of this is the limited
generalisability of findings. In recent years there has been
a shift towards pragmatic RCTs, in which more heteroge-
neous patients group are recruited. In these trials the
reported average effect of treatment may obscure a wide
variation in individual responses, with some patients
showing dramatic improvement while others hardly
respond to the same intervention [50]. One solution may
be to offer more complex or more intensive interventions
only to those patients who do not respond to initial treat-
ment. The effectiveness of such a stepped care approach is
currently being evaluated in a trial with patients with
whiplash-related disorders [38]. Treatment effectiveness
may also be improved by closer matching of treatments to
individual patients' characteristics. Secondary analyses of
a trial with back pain patients comparing a psychosocial
intervention to usual primary care showed that profiles of
patients responding favorably to treatment differed
between intervention groups even though the effects
measured at group level showed no difference at all [50].
The main challenge is how to select or subgroup patients
that may benefit more from specific (or targeted) inter-
ventions. Prediction rules have been designed to identify
patients responding particularly well to some non-phar-
macological interventions [51,52] and a community-
based intervention has been developed to identify and tar-
get psychosocial risks in individual patients [53]. Further
research is needed to establish whether the use of predic-
tion rules (prognostic stratification) indeed leads to better
patient outcomes and more efficient care [39]. As such tri-
als address complex interventions and have more sophis-
ticated designs, they require large sample sizes. They also
tend to require several phases of developmental work, for
example as described by the MRC framework for the
development and evaluation of complex interventions
[54,55].
Agreed priority – Health economic and cost-effectiveness 
analysis
The economic burden of musculoskeletal conditions has
been well documented [56]. For low back pain in the
United States alone these costs are over $100 billion per
year [57] and much of these costs result from prolonged
care for those patients who fail to recover and progress to
chronic disability. An important goal of primary care
interventions is thus to reduce the likelihood of, and costs
associated with, chronicity and ongoing management
[58]. Including health economic alongside clinical out-
comes in RCTs is needed to be able to fully evaluate inter-
ventions. This is particularly important when the
differences in clinical outcomes between treatments are
small. Cost-effectiveness analysis, which compares the rel-
ative clinical benefits of different treatments to their rela-
tive costs, can identify treatments that provide the best
value. For example, a recent trial found no significant dif-
ferences in clinical outcomes between two non-pharma-
cologic interventions for patients with low back or neck
pain; an approach based on cognitive-behavioural princi-
ples versus one based on the McKenzie approach to
mechanical diagnosis and therapy [59]. The economic
analysis included the clinical outcomes, the relative costs
of each approach and of additional health care services,Page 6 of 10
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gested the McKenzie approach was preferable [60]. Thus
including health economic analysis is an important prior-
ity for future research to assist policy makers and patients
in making decisions about interventions.
Agreed priorities – Outcome measures
The need to develop robust patient-based outcome meas-
ures and core sets of these for use within RCTs has been
previously recognised as important within the general
clinical trial literature [61] and within the musculoskeletal
pain community. For example, the OMERACT initiative
http://www.omeract.org/, an informal international net-
work of health professionals that organizes meetings
focused on outcome measurement across RCTs and obser-
vational studies [62] recognised the need for patients to
actively participate in this activity. There are now excellent
opportunities to use such core outcome sets within RCTs
with musculoskeletal pain patients. In collaboration with
OMERACT, disease specific outcome measures for RCTs
have been recommended [e.g. [63,64]]. In the area of low
back pain, an international group of researchers consid-
ered recommendations for standardised outcome meas-
urement in clinical trials [65], whilst others have
evaluated a core set of outcomes for whiplash-related dis-
orders [66]. Not every musculoskeletal condition is cov-
ered but, increasingly, consensus on the important core
domains is being reached. The development and use of
patient-individualised measures are relatively rare but of
increasing interest, as they allow the respondent to select
issues or domains that are of personal concern rather than
those which are solely predetermined by the investigator's
list of questionnaire items [61]. Some such patient-indi-
vidualised measures are available [e.g. [67]] and the suit-
ability of using traditional outcomes alone for
musculoskeletal pain patients questioned [68]. Alongside
broadening the specific choice of outcomes is the possibil-
ity of revisiting the timing of outcome measurements in
RCTs for common musculoskeletal conditions and con-
sidering the trajectory of the pain condition over time as
an outcome rather than focusing on specified follow-up
time points alone.
Strengths and limitations
We consider key strengths of this consensus initiative to
include the independent generation of recommendations
for future research, their independent ranking by both
national and international researchers, clinicians and user
representatives and the level of consensus reached by the
top seven priorities. Participation in the workshops was
excellent, from a wide range of disciplines, an indication of
the relative importance placed on this topic by the commu-
nity of researchers. Overall, participants wanted to
acknowledge the positive progress made over recent years,
in providing many high quality RCTs of non-pharmacolog-
ical interventions for musculoskeletal conditions. There are
now more clinical trialists within disciplines such as physi-
otherapy, occupational therapy and podiatry, than ever
before, who aim to provide patients, practitioners and
health policy makers with reliable evidence about non-
pharmacological therapies. The workshops provided
opportunity for discussion, debate and sharing of ideas and
there was a great deal of enthusiasm for future similar
opportunities. Potential weaknesses, as with all efforts to
generate consensus, are that different participants may have
provided different recommendations or prioritised the rec-
ommendations differently. Inevitably the results of prior-
ity-setting initiatives are dependent on the composition of
the group of participants and further consensus-based initi-
atives in other countries and with other clinical disciplines
would be useful. In addition, our focus was specifically on
recommendations for future studies testing the effective-
ness of non-pharmacological interventions for common
musculoskeletal pain. Clearly, other types of research are
also needed, such as research that provides better under-
standing of aetiological factors and mechanisms of action
of interventions.
Implications
As a whole, this study should be considered as a step
towards improved quality and innovation in future inter-
vention studies, testing the effectiveness of non-pharma-
cological, primary-case based treatment options for
musculoskeletal pain. The lessons learnt from previous
trials, and the priorities identified can guide the develop-
ment of further work of those involved in designing RCTs
within the field of musculoskeletal care. The value of the
agreed priorities will ultimately be in their use, for exam-
ple, in justifying the case for funding of new studies, in
their uptake by funding agencies as part of their commis-
sioning processes and strategic plans, in the incorporation
of these recommendations within new RCTs of non-phar-
macological therapies, and in an increase in translational
research studies that improve research into practice for
patients with musculoskeletal conditions [69]. We hope
these recommendations will be incorporated within new
clinical trial proposals, help to develop future research
collaborations to ensure standardisation of outcome
measures that can facilitate future meta-analyses and sec-
ondary outcome syntheses, lead to an increase in the use
of more innovative trial designs and encourage the pub-
lishing of clinical trial protocols in this field. We welcome
suggestions of other national and international dissemi-
nation mechanisms for these research priorities, such as
the involvement of relevant professional bodies, clinical
interest groups and funding agencies.
Conclusion
Using a consensus approach, we have developed a set of
priorities for the future research agenda, to guide studies
testing the effectiveness of non-pharmacological interven-
tions for patients with musculoskeletal pain. From 22 rec-Page 7 of 10
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internationally. These priorities have the potential to
improve future clinical trials and therefore to provide
more informative guidance to patients and practitioners.
Widespread dissemination of these agreed priorities will
optimise their usefulness.
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